Eftilagimod alpha (IMP321) Emerging Drug Insight and Market Forecast - 2035

“Eftilagimod alpha (IMP321) Emerging Drug Insight and Market Forecast - 2035” report provides comprehensive insights about Eftilagimod alpha (IMP321) for LAG-3 Next-generation Immunotherapies in the 7MM. A detailed picture of the Eftilagimod alpha (IMP321) for LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2035 is provided in this report along with a detailed description of the Eftilagimod alpha (IMP321) for LAG-3 Next-generation Immunotherapies . The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Eftilagimod alpha (IMP321) market forecast, analysis for LAG-3 Next-generation Immunotherapies in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in LAG-3 Next-generation Immunotherapies.

Drug Summary

Eftilagimod alpha is a recombinant protein consisting of a dimer of LAG-3 that has been engineered to be soluble rather than expressed on the surface of cells. It is a first-in-class antigen-presenting cell (APC) activator, which has been proven to induce sustained immune responses in cancer patients when used at a low dose, as a cancer vaccine adjuvant, or used at higher doses to get a systemic effect (i.e. general APC activation). The drug binds to a subset of MHC class II molecules to mediate antigen-presenting cells and CD8 T-cell activation. Investigators hypothesized that the stimulation of the dendritic cell network and subsequent T-cell recruitment could lead to stronger antitumor responses when used in combination with pembrolizumab vs. pembrolizumab alone.

In addition, it has been shown to be safe and well-tolerated, thus making it an ideal combination partner for other drugs or drug candidates. The clinical trials with eftilagimod alpha are combination trials with either chemotherapy or immunotherapy.

Active Immunotherapy PAClitaxel (AIPAC) is Immutep's most advanced and largest clinical trial. It is a Phase IIb clinical trial evaluating eftilagimod alpha (known as efti or IMP321) in combination with a taxane-based chemotherapy called paclitaxel in patients with hormone receptor positive metastatic breast cancer (MBC) as an immunotherapy. This combination treatment aims to boost the immune response against tumor cells compared to the chemotherapy treatment alone.

AIPAC is a potentially pivotal trial, meaning that subject to sufficient and clinically meaningful data and regulatory interactions, the final read-out of data could serve as a basis to pursue regulatory approval pathways for eftilagimod alpha with the European Medicines Agency and the US Food and Drug Administration.

Eftilagimod alpha is under evaluation for a variety of solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and HER2-/HR+ metastatic breast cancer. Its favorable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Eftilagimod alpha (IMP321) description, mechanism of action, dosage and administration, research and development activities in LAG-3 Next-generation Immunotherapies .
• Elaborated details on Eftilagimod alpha (IMP321) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Eftilagimod alpha (IMP321) research and development activity in LAG-3 Next-generation Immunotherapies in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Eftilagimod alpha (IMP321).
• The report contains forecasted sales of Eftilagimod alpha (IMP321) for LAG-3 Next-generation Immunotherapies till 2035.
• Comprehensive coverage of the late-stage emerging therapies for LAG-3 Next-generation Immunotherapies.
• The report also features the SWOT analysis with analyst views for Eftilagimod alpha (IMP321) in LAG-3 Next-generation Immunotherapies.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Eftilagimod alpha (IMP321) Analytical Perspective

In-depth Eftilagimod alpha (IMP321) Market Assessment

This report provides a detailed market assessment of Eftilagimod alpha (IMP321) in LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2035.

Eftilagimod alpha (IMP321) Clinical Assessment

The report provides the clinical trials information of Eftilagimod alpha (IMP321) in LAG-3 Next-generation Immunotherapies covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for LAG-3 Next-generation Immunotherapies is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Eftilagimod alpha (IMP321) dominance.
• Other emerging products for LAG-3 Next-generation Immunotherapies are expected to give tough market competition to Eftilagimod alpha (IMP321) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Eftilagimod alpha (IMP321) in LAG-3 Next-generation Immunotherapies.
• This in-depth analysis of the forecasted sales data from 2023 to 2035 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Eftilagimod alpha (IMP321) in LAG-3 Next-generation Immunotherapies.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Eftilagimod alpha (IMP321)?
• What is the clinical trial status of the study related to Eftilagimod alpha (IMP321) in LAG-3 Next-generation Immunotherapies and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Eftilagimod alpha (IMP321) development?
• What are the key designations that have been granted to Eftilagimod alpha (IMP321) for LAG-3 Next-generation Immunotherapies?
• What is the forecasted market scenario of Eftilagimod alpha (IMP321) for LAG-3 Next-generation Immunotherapies?
• What are the forecasted sales of Eftilagimod alpha (IMP321) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in LAG-3 Next-generation Immunotherapies and how are they giving competition to Eftilagimod alpha (IMP321) for LAG-3 Next-generation Immunotherapies?
• Which are the late-stage emerging therapies under development for the treatment of LAG-3 Next-generation Immunotherapies?

This product will be delivered within 2 business days.